DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
ADA581334
Title:
Biomimetics for Treating Biofilm-Embedded Infections
Descriptive Note:
Final rept. 16 Sep 2010-15 Sep 2012
Corporate Author:
POLYMEDIX INC RADNOR PA
Report Date:
2012-12-17
Pagination or Media Count:
18.0
Abstract:
Small mimics of host defense proteins smHDPs were screened for anti-film activity. The most potent compounds eradicated MRSA biofilms at concentrations superior to gentamycin and other commonly used antibiotics. Select compounds also demonstrated activity against E. coli and P. aeruginosa biofilm cultures. Several compounds were also tested in an alternate in vitro biofilm assay for evaluation in a topical wound biofilm model. The compounds showed strong in vitro activity against S. aureus and P. aeruginosa biofilms and activity was superior over mupirocin ointment. Seven smHDPs were tested in a stringent mouse biofilm model examining activity against biofilm-impregnated catheters implanted subcutaneously. None of the PMX compounds tested in the model were efficacious. Several compounds were evaluated in a topical wound biofilm model. MRSA biofilms were pre-formed for 24 hours in partial-thickness mouse wounds and treated with hydrogel formulations. Both compounds achieved log10 reductions of 5-6 with twice daily application and log10 reductions of 3-4 even when applied only once daily. Although the goal of identifying biofilm-active smHDPs following systemic administrations, we have been successful in identifying highly active smHDPs in a topical wound biofilm model. These results indicate that smHDPs are promising candidates for topical treatment of biofilm infections in wounds.
Distribution Statement:
APPROVED FOR PUBLIC RELEASE
